David R Parkinson

President and CEO of Nodality, Inc., a San Francisco-based biotechnology company developing next-generation diagnostics in oncology and auto-immune diseases to enable more personalized treatment approaches. Before leading Nodality, Dr. Parkinson was Senior Vice President, Oncology Research and Development at Biogen Idec. He previously served as Vice President, Oncology Development, at Amgen and Vice President, Global Clinical Oncology Development at Novartis, where he was instrumental in bringing Gleevec® to market, completely transforming the treatment of Chronic myelogenous leukemia (CML). Prior to this, he served as the National Cancer Institute’s Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program. Dr. Parkinson has also served as the Chairman of the U.S. Food and Drug Administration (FDA) Biologics Advisory Committee and was a recipient of the FDA's Cody Medal. Dr. Parkinson received his medical degree from the University of Toronto Faculty of Medicine and he received Internal Medicine and Hematology/Oncology training at McGill University and at New England Medical Center.